COMPASS Pathfinder Ltd : COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association s inaugural Scholars programme finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
(0)
LONDON, June 03, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS) ( COMPASS ), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I study showing that its COMP360 psilocybin had no clinically-relevant negative effect on cognitive function, when administered to healthy adult volunteers with support from specially trained therapists.
The data) from the randomised, double-blind, placebo-controlled, phase I trial conducted at King s College London, will be presented today at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, by Dr James Rucker, Consultant Psychiatrist and Senior Clinical Lecturer in Psychopharmacology at King s College London s Institute of Psychiatry, Psychology and Neuroscience (IoPPN). Initial results from the study were published in December 2019. The results published today present a more in-depth analysis of cognitive
COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers
COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I study showing that its COMP360 psilocybin had no clinically-relevant negative effect on cognitive function, when administered to healthy adult volunteers with support from specially trained therapists. The data from the randomised, …
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I study showing that its COMP360 psilocybin had no clinically-relevant negative effect on cognitive function, when administered to healthy adult volunteers with support from specially trained therapists.
(0)
Highlights:
New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
Two further US patents granted
Equity financing raises gross proceeds of $144 million
Phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD) on track to report data by end of 2021
Wayne J Riley MD joins Board of Directors and Anne Benedict is appointed Chief People Officer
Conference call today at 1:00pm UK (8:00am ET)
LONDON, May 13, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS) ( COMPASS ), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2021 and gave an update on recent progress across its business.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
COMPASS Pathways announces pricing of public offering
COMPASS Pathfinder Ltd.April 30, 2021 GMT
London, UK, 30 April 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of its public offering of 4,000,000 American Depositary Shares (“ADSs”) representing 4,000,000 ordinary shares at a public offering price of $36.00 per ADS for total gross proceeds of $144.0 million. All ADSs sold in the offering were offered by COMPASS. The offering is expected to close on or about 4 May 2021, subject to the satisfaction of customary closing conditions. In addition, COMPASS has granted the underwriters a 30-day option to purchase up to an additional 600,000 ADSs at the public offering price, less underwriting discounts and c